Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study

Data from the SEER-Medicare (1999-2017) database was assessed, looking at the differences in survival between non-Hispanic Black (NHB) and non-Hispanic white (NHW) patients with multiple myeloma. NHB patients with MM were less likely to receive novel antimyeloma treatment and ASCT compared with NHWs, and these disparities in treatment could not be explained by sociodemographic factors. Overall survival was comparable between across the entire population, but NHB patients had a superior survival when they were treated similar as NHW patients.